Literature DB >> 14681760

Subacute sclerosing panencephalitis in two brothers.

S Vieker1, J J Schmitt, C Behrens, B Weissbrich, H Hartmann.   

Abstract

We report the occurrence of subacute sclerosing panencephalitis (SSPE) in two brothers two years after measles infection. The diagnosis was confirmed by compatible data from medical history, occurrence of autochthonic measles virus (MV) IgG production in the central nervous system (CNS), and pathognomonic EEG changes. Pathogenetically, SSPE is caused by a genome mutation of intracellularly persisting MV, causing viral nucleocapsides to accumulate in the brain cells. A specific predisposing immune defect is not known. The occurrence of two cases in one family is suggestive of a genetic predisposing factor.

Entities:  

Mesh:

Year:  2003        PMID: 14681760     DOI: 10.1055/s-2003-44672

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  4 in total

Review 1.  Subacute sclerosing panencephalitis.

Authors:  Ravindra Kumar Garg
Journal:  J Neurol       Date:  2008-10-14       Impact factor: 4.849

2.  Genetic characterization of measles virus genotype D6 subacute sclerosing panencephalitis case, Alberta, Canada.

Authors:  K Pabbaraju; K Fonseca; S Wong; M W Koch; J T Joseph; G A Tipples; R Tellier
Journal:  J Neurovirol       Date:  2018-10-05       Impact factor: 2.643

3.  Subacute sclerosing panencephalitis in papua new guinean children: the cost of continuing inadequate measles vaccine coverage.

Authors:  Laurens Manning; Moses Laman; Henry Edoni; Ivo Mueller; Harin A Karunajeewa; David Smith; Ilomo Hwaiwhanje; Peter M Siba; Timothy M E Davis
Journal:  PLoS Negl Trop Dis       Date:  2011-01-04

Review 4.  Subacute sclerosing panencephalitis in pregnancy.

Authors:  Michael H Chiu; Bonnie Meatherall; Ana Nikolic; Kristine Cannon; Kevin Fonseca; Jeffrey T Joseph; Judy MacDonald; Kanti Pabbaraju; Raymond Tellier; Sallene Wong; Marcus W Koch
Journal:  Lancet Infect Dis       Date:  2016-01-20       Impact factor: 25.071

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.